Open Access

The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy

  • Authors:
    • Rui Zhang
    • Xin Sun
    • Bo Niu
  • View Affiliations

  • Published online on: October 16, 2017     https://doi.org/10.3892/etm.2017.5307
  • Pages:6002-6006
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: PDF 0 views | HTML 0 views
0

Abstract

The aim of the present study was to report the importance of pegaptanib sodium (PGSD) injection treatment for vascular active vitreoretinopathy (VAVR). A total of 82 patients with VAVR diagnosed by increasing subretinal exudation were enrolled and received a single intravitreal injection of PGSD. The efficacies of PGSD for patients with VAVR were analyzed using photography, fluorescein angiography and optical coherence tomography. The pathological changes in vascular activity, amount of exudation and visual acuity between the PGSD, and placebo group were also compared. The results demonstrated that the PGSD injection significantly decreased subretinal exudation and leakage compared with the placebo when assessed using fluorescein angiography in a 12‑month follow‑up. It was observed that the PGSD injection inhibited inflammatory cytokines interleukin‑1β and tumor necrosis factor α for patients with VAVR compared with the placebo. Furthermore, results demonstrated that the average inflammation score and intraocular pressure was significantly decreased compared with the placebo. Visual acuity was improved from 1.3 to 0.7 in the majority of patients in the PGSD group. In conclusion, the outcomes of the present study indicate that the PGSD intravitreal injection is an efficient treatment option for patients with VAVR.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, R., Sun, X., & Niu, B. (2017). The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy. Experimental and Therapeutic Medicine, 14, 6002-6006. https://doi.org/10.3892/etm.2017.5307
MLA
Zhang, R., Sun, X., Niu, B."The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy". Experimental and Therapeutic Medicine 14.6 (2017): 6002-6006.
Chicago
Zhang, R., Sun, X., Niu, B."The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy". Experimental and Therapeutic Medicine 14, no. 6 (2017): 6002-6006. https://doi.org/10.3892/etm.2017.5307